4.0 Patient Selection and Registration 
4.1 Eligibility 
4.11 Age 18 years or older with no significatnt medical problems. Nonpregnant females. 
4.12 Recurrent residual glioblastoma multiforme of the brain with measurable disease on 
enhanced CT or MRI. Imaging studies must be performed within two weeks of starting treatment. 
4.13 HLA-A2 haplotype 
4.14 Autologous tumor established as continuous culture in vitro. 
4.15 Patients must have failed surgery and radiation therapy. Prior chemotherapy is not 
required. However, patients receiving prior treatment, including chemotherapy must wait 6 weeks before 
starting treatment. Patients with rapidly progressive tumors (e.g. at the rate that indicates that waiting 6 
weeks is medically inadvisable) may enter treatment if adverse effects of prior treatment have been 
resolved. 
4.16 Expected survival must be at least 3 months. 
4.17 Kamofsky performance of > 60%. 
4.18 Baseline hematology and chemistry studies: hemoglobin > 9.9 gm/dl, total granulocyte 
count > 1,999/mm^, platelet count > 124,000/mm^, BUN < 30mg/dl, creatinine < 2mg/dl, alkaline 
phosphatase and SGOT < 2x normal upper limit of normal, amylase, lipase < 1.5x upper limit of normal. 
These studies must be performed within a week prior to starting therapy. 
4.19 Informed Consent: All patients must be aware of the neoplastic nature of his/her disease 
and willingly consent after being informed of the procedures to be performed, the experimental nature of 
the therapy, alternatives, potential benefits, side effects, risks and discomforts. Human protection 
committee approval of this protocol and consent form is required. 
4.2 Registration 
4.21 All patients must be enrolled onto study through the San Diego Regional Cancer Center 
prior to starting therapy. To register a patient, contact Colette Carson, R.N. , Clinical Trials Registrar 
(619-450-5990) 
. Please provide the following information: 
[624] 
Recombinant DNA Research, Volume 19 
